Real-world treatment and utilization of venetoclax for incident acute myeloid leukemia in a Medicare population
A growing number of patients enrolled in Medicare Fee-For-Service with AML use first-line venetoclax. Older patients and those with comorbidities are less likely to initiate second-line therapy. Costs were lower and length of stay was shorter than described in previous research.
Authors
- Elizabeth A. Donckels (ORCID: https://orcid.org/0000-0003-0229-6047)
- Jia Ma (ORCID: https://orcid.org/0000-0003-1819-9428)
- Ilya Okunev (ORCID: https://orcid.org/0000-0002-7092-225X)
- Joshua A. Roth (ORCID: https://orcid.org/0000-0001-6621-8342)
- Allison Petrilla (ORCID: https://orcid.org/0000-0002-5056-4897)
- T. Alexander Russell-Smith (ORCID: https://orcid.org/0000-0003-1445-8138)
- Simon Purcell
- Joseph C. Cappelleri (ORCID: https://orcid.org/0000-0001-9586-0748)
- Anthony Yu (ORCID: https://orcid.org/0009-0005-5238-6464)
- Paul G. D'Amico (ORCID: https://orcid.org/0009-0005-4276-8821)
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Bowie State University (US)
- Inova Design Solutions (United Kingdom) (GB)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1080/14796694.2025.2587568
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00